167 - Putting “PEP” to the Step: Doxycycline Post-Exposure Prophylaxis

Tuesday, October 21, 2025

1:45 PM - 3:00 PM US ET

Location: Sidney J. Marcus Auditorium

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Yussef Bennani, MD, MPH (he/him/his)

Associate Professor of Medicine
Virginia Commonwealth University Health System
Richmond, VA, United States
Jenell Stewart, DO, MPH (she/her/hers)

Assistant Professor
Hennepin Healthcare and University of Minnesota
Minneapolis, MN, United States

Faculty(s)

Kenneth H. Mayer, MD (he/him/his)

Medical Research Director
The Fenway Institute
Fenway Health
Boston, MA, United States
VC

Victoria Chu, MD MPH (she/her/hers)

Assistant Professor
University of California, San Francisco
San Francisco, CA, United States
Wesley Kufel, PharmD, BCPS, BCIDP, FCCP, FIDSA

Clinical Associate Professor
State University of New York at Binghamton School of Pharmacy and Pharmaceutical Sciences
Binghamton, NY, United States

Disclosure(s):

Yussef Bennani, MD, MPH: No financial relationships to disclose.

Jenell Stewart, DO, MPH: No financial relationships to disclose.

Kenneth H. Mayer, MD: Gilead Biosciences: Advisor/Consultant, Grant/Research Support; GSK/ViiV Healthcare: Advisor/Consultant, Grant/Research Support; Merck and Company, Inc.: Advisor/Consultant, Grant/Research Support; Moderna, Inc.: Grant/Research Support

Victoria Chu, MD MPH: No financial relationships to disclose.

Wesley D. Kufel, PharmD, BCPS, BCIDP, FCCP, FIDSA: Merck and Company, Inc.: Grant/Research Support; Shionogi, Inc.: Honoraria

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe evidence supporting use of doxycycline prophylaxis for the prevention of Lyme disease;
employ Doxy-PEP for prevention of STI’s using the most recent evidence-based data;
identify patients who would most benefit from use of Doxy-PEP for STI prevention;
recognize risk of anti-microbial resistance with the use of Doxy-PEP for STI prevention.

Presentations:

1:45 PM - 2:10 PM US ET

Doxycycline Post-Exposure Prophylaxis for Lyme Disease Prevention
Speaker: Wesley D. Kufel, PharmD, BCPS, BCIDP, FCCP, FIDSA – State University of New York at Binghamton School of Pharmacy and Pharmaceutical Sciences
2:10 PM - 2:35 PM US ET

Doxycycline Post-Exposure Prophylaxis for STI’s – Where We Are Now and What the Future May Hold
Speaker: Kenneth H. Mayer, MD (he/him/his) – Fenway Health
2:35 PM - 3:00 PM US ET

DoxyPEP and Antimicrobial Resistance: What We Know So Far
Speaker: Victoria Chu, MD MPH (she/her/hers) – University of California, San Francisco